~Acting Attorney General says change will expand research; DEA opens expedited proceedings as White House executive order takes effect — industry and advocates react to a historic federal shift.~
WASHINGTON, USA:--- In a sweeping policy shift that could reshape federal control of cannabis, the Department of Justice on Thursday issued an order immediately placing Food and Drug Administration–approved marijuana products and marijuana products governed by qualifying state medical licenses into Schedule III of the Controlled Substances Act, while launching an expedited administrative hearing to consider broader rescheduling of marijuana from Schedule I to Schedule III. The move implements President Trump’s December 18, 2025, executive order directing faster federal action to increase medical marijuana research.
What the government announced: Acting Attorney General Todd Blanche signed the order that, for the first time, treats certain FDA-approved marijuana products and state-regulated medical marijuana under Schedule III — a lower schedule that recognizes accepted medical uses and carries less severe regulatory restrictions than Schedule I. The DOJ and the Drug Enforcement Administration also published a new notice setting an administrative hearing to begin June 29, 2026, to consider the comprehensive rescheduling of marijuana. Officials said the changes are intended to expand medical research while preserving law enforcement tools to combat illicit trafficking.
“The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options,” Acting Attorney General Blanche said in the announcement. DEA Administrator Terry Cole said the agency would move “expeditiously” through the administrative hearing process while continuing enforcement against cartels and fentanyl threats.
What Schedule III means and why it matters: Under federal law, substances placed in Schedule III are recognized as having accepted medical uses and are subject to DEA oversight with less stringent controls than Schedule I or II drugs — for example, Schedule III substances may be prescribed and dispensed under established prescription rules and typically allow refills under federal pharmacy regulations. Advocates and industry lawyers say rescheduling could make it easier for physicians and researchers to obtain and study cannabis, and could reduce legal friction for state-licensed producers; however, it does not legalize cannabis federally or automatically erase prior criminal penalties for unauthorized possession or distribution.
Cannabis industry groups and officials in states with medical programs welcomed the decision as long sought federal recognition that could remove research barriers, improve patient access to approved therapies, and ease some tax and banking restrictions that have complicated state markets. At the same time, advocates and some lawmakers cautioned that rescheduling alone will not resolve all legal and financial conflicts between federal and state law, and urged Congress to enact more comprehensive reforms. News outlets and legal analysts note the White House directive prompted the DOJ timeline and that further changes will depend on the outcome of the DEA administrative process.
Legal and business implications: Legal experts say rescheduling to Schedule III would alter regulatory pathways for research and drug development and could affect tax treatment for state-licensed operators that were previously barred from certain federal deductions under Internal Revenue Code Section 280E. Banking access and interstate commerce questions remain complex: while Schedule III status may ease some compliance burdens, many federal statutes and regulations — and a range of state laws — would still govern how cannabis is produced, sold, and transported. Law firms and policy analysts are already advising clients to prepare for rapid regulatory changes once the DEA’s new rulemaking and hearings proceed.
The DOJ said it will withdraw prior notices and proceedings that began under the previous administration and proceed under the new expedited schedule with firm deadlines; the administrative hearing beginning on June 29, 2026, will be central to whether marijuana as a whole is redesignated to Schedule III. If the DEA ultimately adopts broader rescheduling through the rulemaking, federal regulatory frameworks for prescribing, research approvals, manufacturing controls, and enforcement could change significantly — but experts emphasize that many details would be worked out in follow-on HHS, FDA, and DEA rulemaking and guidance. justice.gov
Voices of concern: Some public health groups and opponents warn that loosening federal scheduling without robust federal research and safety monitoring could have unintended consequences, especially for youth and vulnerable populations. Others pressed for concurrent legislative fixes to address issues that rescheduling would not automatically resolve, such as expungement of past convictions and clear banking reforms. Coverage from national outlets in recent months framed the executive order as a major policy pivot that will generate both opportunity and controversy as federal and state authorities adjust.
The DOJ’s action marks a historic federal step toward aligning national drug policy with changing state laws and growing interest in cannabis research. The coming weeks and months — capped by the June 29, 2026, administrative hearing and subsequent rulemaking — will determine how far the federal government goes in loosening restrictions and how quickly patients, researchers, and businesses feel the effects of the shift. Readers should expect a steady stream of regulatory announcements, legal analyses, and state-level responses as agencies, courts, and Congress respond.
For Official Publication:https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana